The Parkinson's UK Drug Club is an innovative research initiative launched by Parkinson's UK in 2017 to identify and accelerate the development of existing drugs that could be repurposed as treatments for Parkinson's disease. The program takes a systematic, scientific approach to screening approved drugs for potential neuroprotective effects in Parkinson's, leveraging the charity's investment in research and their extensive network of researchers and people affected by Parkinson's.
The Drug Club represents a paradigm shift in Parkinson's research funding, focusing on near-term clinical translation rather than basic discovery. By identifying drugs that already have established safety profiles, the program aims to bring potential disease-modifying treatments to patients much faster than traditional drug development pathways.
The program operates through a structured framework:
| Component | Description |
|---|---|
| Scientific Advisory Board | Expert researchers evaluating compounds |
| Drug Screening Pipeline | Systematic evaluation of candidates |
| Clinical Trials Network | UK centers for trial execution |
| Patient Cohort | Pre-screened patients for rapid recruitment |
Parkinson's UK commits substantial resources to the Drug Club:
The Drug Club prioritizes drugs targeting key Parkinson's disease mechanisms:
| Pathway | Target | Example Drugs |
|---|---|---|
| Neuroinflammation | Microglial activation | Minocycline, Ibuprofen |
| Mitochondrial function | Complex I, ATP production | CoQ10, Creatine |
| Neurotrophic factors | GDNF, BDNF | Exercise, gene therapy |
| Protein clearance | Autophagy, UPS | Rapamycin, Nilotinib |
| Calcium homeostasis | L-type channels | Amlodipine |
Drugs considered for the program must meet:
| Drug | Original Use | PD Target | Status |
|---|---|---|---|
| Simvastatin | High cholesterol | Neuroprotection | Phase II |
| Ambroxol | Mucolytic | GBA enhancement | Phase II |
| Inosine | Gout | Urate elevation | Phase II/III |
| Metformin | Diabetes | AMPK activation | Phase II |
| Drug | Trial Phase | Outcome |
|---|---|---|
| Exenatide | Phase II | Positive - advancing |
| GLP-1 agonists | Phase II | Positive signals |
| Year | Investment | Trials Funded |
|---|---|---|
| 2017 | £2.5M | 3 |
| 2018 | £3.2M | 4 |
| 2019 | £2.8M | 3 |
| 2020 | £2.1M | 2 |
| 2021 | £2.4M | 3 |
The Drug Club leverages Parkinson's UK volunteer networks for:
The Drug Club is expanding its focus to:
The Drug Club is evaluating several new candidates:
| Drug | Original Indication | PD Target | Development Stage |
|---|---|---|---|
| Sargramostim | Neutropenia | Immunomodulation | Phase I |
| Lithium | Bipolar disorder | Neuroprotection | Preclinical |
| GLP-1 agonists | Diabetes | Metabolic | Phase II/III |
Drug repurposing offers significant advantages over traditional de novo drug development:
| Advantage | Traditional Development | Drug Repurposing |
|---|---|---|
| Timeline | 10-15 years | 3-5 years |
| Cost | $1-2 billion | $50-100 million |
| Risk | High (80% failure) | Lower (known safety) |
The Drug Club specifically targets drugs that:
The Drug Club is guided by an expert Scientific Advisory Board comprising:
The Drug Club follows a structured review process:
Drug repurposing for Parkinson's offers substantial economic benefits:
The Drug Club faces several challenges:
From previous Drug Club programs:
The Parkinson's UK Drug Club represents an innovative and pragmatic approach to accelerating disease-modifying treatments for Parkinson's disease. By focusing on repurposing existing drugs with known safety profiles, the program aims to bring new therapies to patients faster and more cost-effectively than traditional drug development. With a strong pipeline of candidates and a robust network of academic and industry partners, the Drug Club is well-positioned to make significant contributions to Parkinson's disease treatment.